Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program
Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.
Florida / New York
Ph: 561.316.3330
Medical device and diagnostics companies are always looking for ways to improve their products and services. In the ever-changing landscape of the healthcare industry, it’s essential for these companies to stay ahead of the curve. That’s why funding is always news.
Series A, B, and other rounds of funding are essential for medical device and diagnostics companies. They provide the necessary capital to help these businesses grow and innovate. And with so many investors interested in this space, there are plenty of opportunities for companies to secure the funding they need.
Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.
The XGAL3® therapeutic apheresis device is the early-mover for the treatment of AKI. ETI has demonstrated significant survival benefits in preclinical models and their prototype device has successfully removed GAL-3 from human blood plasma.
Fidmi Medical CEO Shahar Millis remarked, “We are truly excited to embark on the market entry phase for Fidmi. With FDA clearance and strategic collaboration with Micro-Tech, a leader in this field, we are well-positioned to make a real difference for people requiring long-term nutritional support.”
Copyright © 2025 Medical Device News Magazine, a division of PTM Healthcare Marketing, Inc. All Rights Reserved
Hours:
M – F 8 am – 5 pm
Florida / New York
Phone: 561.316.3330